Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Release

Printer Friendly Version View printer-friendly version
<< Back
Spring Bank Pharmaceuticals Announces a Poster Presentation of its lead STING Agonist, SB 11285, at the 2017 AACR Conference on Tumor Immunology and Immunotherapy in Boston, MA

Data to highlight recent preclinical studies of SB 11285, a novel next-generation STING agonist

HOPKINTON, Mass., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced a planned poster presentation highlighting recent preclinical data for the next-generation STING (STimulator of INterferon Genes) agonist, SB 11285, at the AACR Conference on Tumor Immunology and Immunotherapy in Boston, MA.

Details of the presentation are as follows:

     
Title:   Pharmacodynamic and preclinical studies of SB 11285, a highly potent, and systemically bioavailable STING agonist as a novel immunotherapeutic agent
Date:   Monday, October 2, 2017 (Poster Session A)
Time:   5:30 p.m. to 7:30 p.m.
Location:   Boston Marriott Copley Place, Boston, MA
     

About the AACR Special Conference on Tumor Immunology and Immunotherapy

The conference will highlight recent advances in understanding the range of immune responses towards cancer and how these can be modified and harnessed for prevention and therapeutics. This year’s program will focus on mechanisms, models, and novel technologies all geared towards a deeper understanding of the immunologic science of the cancer cell in order to design better treatments. The conference will take place October 1-4 at the Boston Marriott Copley Place, Boston, MA.

About Spring Bank

Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus (HBV) and other SMNH product candidates, including SB 11285, the Company’s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STING pathway.

Forward-Looking Statements 

Statements in this press release about Spring Bank's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Spring Bank’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether Spring Bank’s product candidates will advance through the clinical trial process on a timely basis, or at all; whether the results of such trials will warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether Spring Bank's product candidates will receive approval from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of Spring Bank's Annual Report on Form 10-K for the year ended December 31, 2016, which was filed with the Securities and Exchange Commission (SEC) on February 14, 2017, Spring Bank's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, which was filed with the SEC on July 31, 2017, and in other filings Spring Bank makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof. Spring Bank anticipates that subsequent events and developments will cause Spring Bank’s views to change. However, while Spring Bank may elect to update these forward-looking statements at some point in the future, Spring Bank specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spring Bank’s views as of any date subsequent to the date hereof.

Contacts 

For investor inquiries: 
Spring Bank Pharmaceuticals, Inc.
Jonathan Freve
Chief Financial Officer
(508) 473-5993

LifeSci Advisors, LLC
Andrew McDonald
LifeSci Advisors, LLC
646-597-6987
Andrew@LifeSciAdvisors.com

Primary Logo

Source: Spring Bank Pharmaceuticals Inc.